Insider buying last 90 days
No open-market insider purchases were filed for LH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LH insider filing, plotted on the chart in Gekko.Open LH in Gekko
Gekko Brief
AI summaryNov 4 closeLabcorp moved higher this week following strong Q3 earnings, upgraded full-year revenue guidance, and new collaborations, which drove a 43.6% year-to-date stock surge and prompted questions about whether shares are now fully valued. The company also announced that CFO Julia Wang will speak at the UBS Global Healthcare Conference on November 10, 2026. Alongside this, several Form 4 filings disclosed insider transactions, including a sale of 1,078 shares by director Richelle P. Parham at $361.22 per share.
LH closed at $367.79, up 3.9%, sitting above both its 50-day average of $324.50 and 200-day average of $288.88, with the shorter average above the longer one, reflecting a supportive trend. The GekkoIndex reads 43.2, placing the stock in the Distribution zone, up 8.1 over five sessions. Price sits 6.1% above Gekko Fair Value of $346.56, a gap worth noting given the recent run, with the 52-week range spanning $244.52 to $371.
Labcorp's next earnings report is scheduled for 16 February 2027, 103 days out and beyond a typical 20-trading-day hold. Over the last 90 days, Congress recorded 1 buy and 0 sells. Thirteen analysts cover the stock, with 10 at buy and 3 at hold, and a consensus target of $382.25 implying 3.9% upside. Seasonally, the next 20 trading days have averaged a 4.5% gain over 5 years, positive in 5 of them, while typical 20-day moves run near 4.4%.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Labcorp price vs fair value
Close $367.79200-day averageGekko Fair Value $346.56
Labcorp quick facts
- Market cap
- $29.83B
- P/E ratio
- 29.2
- Forward P/E
- 19.2
- EPS, TTM
- $12.20
- Revenue, TTM
- $14.59B
- Profit margin
- 6.9%
- Dividend yield
- 0.80%
- Beta
- 0.83
- Volume
- 773,385 avg 750,407
- 1-year return
- +42.6%
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±4.4%
- 50-day average
- $324.50
- 200-day average
- $288.88
- Next earnings
- Feb 16 before open
- Shares outstanding
- 81.20M
Labcorp swing-trade checklist
Labcorp scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $367.79 is above the 50-day ($324.50) and 200-day ($288.88) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
43.2, Distribution
Reading 43.2 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
6.1% above
Price is 6.1% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 103 days
Next report Feb 16, 2027, 103 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.5% on average
From this point in the calendar, the next 20 trading days averaged +4.5% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Labcorp stock chart and price history
Labcorp closed at $367.79 on Nov 4, 2026, +42.6% over the past year, inside a 52-week range of $244.52 to $371.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +18.0%
- 3 months
- +16.2%
- 6 months
- +43.1%
- 1 year
- +42.6%
The full LH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LH in Gekko
Follow Labcorp through every session
Put LH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LH in GekkoFree for 7 days. No credit card required.
About Labcorp
Labcorp provides diagnostic laboratory testing that helps doctors, hospitals, drug makers, researchers, and individual patients make informed health decisions. The company is best known for this core laboratory testing work, which supports clinical and scientific decision-making across the healthcare field.
Its services reach a wide range of customers, including medical professionals, healthcare facilities, pharmaceutical companies, and scientific investigators, alongside patients who rely on its testing directly. This mix of institutional and individual clients points to a business built around supplying dependable diagnostic information to many parts of the healthcare system.
Labcorp is headquartered in Burlington, North Carolina, and began operations on April 16, 2024. Its shares are listed on the NYSE under the ticker LH.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- labcorp.com
Labcorp GekkoIndex: the smart money zone
Labcorp’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 43.2, in the Distribution zone, up 8.1 points over five sessions.
43.2Distribution
Up 8.1 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | +1.5% | +5.9% | ||
| Accumulation | 221 | +0.9% | +2.9% | ||
| Neutral | 408 | +0.1% | +0.2% | ||
| Distribution (current zone) | 45 | −0.4% | +0.8% | ||
| Selling | 4 | Too few readings yet | |||
Average LH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the LH price, zone by zone.Track LH in Gekko
Is Labcorp stock overvalued? Gekko Fair Value
Labcorp trades 6.1% above Gekko Fair Value of $346.56, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Labcorp shares are worth, recalculated every trading day.
$346.56
Gekko Fair Value, Nov 4, 2026
6.1% Overvalued
At the end of Aug 2026 the price was 1.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open LH in Gekko
Labcorp insider and Congress trading
No open-market insider purchases were filed for Labcorp, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Labcorp has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $353.8M
- As a share of market cap
- 1.19%
- Trailing four quarters
- $701.8M
From company filings.
Labcorp earnings: next date and track record
Labcorp reports on Feb 16, 2027, before the open (103 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 16, 2027
Expected before the open, 103 days away
- EPS estimate
- $4.50
- Revenue estimate
- $3.75B
8 of 8reports beat the EPS estimate
±3.6%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Labcorp reported a strong Q2 2026 with solid organic revenue growth, margin expansion, and double-digit adjusted EPS growth. Enterprise revenue rose ~5.8% year-over-year to ~$3.7B, adjusted operating margin expanded ~70 bps to 15.8%, adjusted EPS grew ~15% to $4.99, and free cash flow was $314M (with full-year FCF guidance of $1.24B–$1.36B). Diagnostics revenue grew ~5.5% driven by specialty testing and rising tests per accession; Biopharma Laboratory Services (BLS) grew ~6.5% driven by Central Labs (book-to-bill 1.14 for the quarter). Management highlighted progress in specialty testing (oncology, neurology, autoimmune, women’s health), Labcorp OnDemand (consumer DTC growth), technology/AI adoption, and strategic actions in Early Development (ED) that are starting to improve margins. Capital allocation activity included $226M in acquisitions, $354M in share repurchases, dividend payments, retirement of $500M senior notes, and an additional $1B share repurchase authorization. Management raised full-year revenue and EPS guidance and reiterated confidence in long-term growth.
- Guidance
- Updated/forward-looking items discussed on the call: - Full-year 2026 adjusted free cash flow guidance: $1.24 billion to $1.36 billion. - Full-year adjusted tax rate expected to be ~23%. - Management increased full-year revenue and EPS guidance (midpoint not numerically disclosed on call), noting the midpoint EPS growth of over ~11% (at the midpoint). - Diagnostics: raised midpoint of diagnostic revenue guidance by ~20 basis points (reclassification of expected corporate revenue into Diagnostics). - BLS/Early Development: Early Development revenue now expected to deliver single-digit growth for full year 2026 (up from flat prior expectation). - Book-to-bill and pipeline metrics: BLS book-to-bill 1.14 in the quarter, 1.03 trailing 12 months. - Board approved an additional $1.0B share repurchase authorization (total outstanding authorization $1.4B).
- Risks flagged
- Risks and headwinds discussed or referenced: - Potential payer/ACA-related headwind: management has assumed ~30 basis points of diagnostic volume impact for ACA-related changes (cohort <4–5% of volume). - Collectibility/bad debt risks (patient responsibility/co-pays) noted as an area to monitor despite current stability. - Regulatory/policy risk: PAMA payment changes and ongoing RESULTS Act/legislative uncertainty; PAMA data submission and potential impact next year. - M&A/integration risk: pipeline and potential hospital lab acquisitions are subject to accretive thresholds and integration risk. - Macroeconomic and election/legislative uncertainty that could affect payer policy and reimbursement.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $4.99 est $4.79 | $3.73B est $3.71B | +0.7% |
| Apr 30, 2026 | $4.25 est $4.12 | $3.54B est $3.51B | −0.5% |
| Feb 17, 2026 | $4.07 est $3.94 | $3.52B est $3.56B | −1.4% |
| Oct 28, 2025 | $4.18 est $4.14 | $3.56B est $3.56B | −10.0% |
| Jul 24, 2025 | $4.35 est $4.17 | $3.53B est $3.49B | +5.8% |
| Apr 29, 2025 | $3.84 est $3.74 | $3.35B est $3.40B | +5.0% |
| Feb 6, 2025 | $3.45 est $3.39 | $3.33B est $3.31B | −1.5% |
| Oct 24, 2024 | $3.50 est $3.49 | $3.28B est $3.26B | +4.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Labcorp stock forecast and analyst price targets
Analysts’ average 12-month price target for Labcorp is $382.25, +3.9% from the last close, from 13 firms rating the stock in the last 90 days.
$382.25consensus 12-month target, +3.9% from the last close
Now $367.79Avg $382.25
Low $340High $420
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 30 | Piper Sandler | $365 | −0.8% |
| Oct 29 | Leerink Partners | $410 | +11.5% |
| Oct 29 | Robert W. Baird | $396 | +7.7% |
| Oct 29 | Truist Financial | $395 | +7.4% |
| Oct 29 | Morgan Stanley | $388 | +5.5% |
+0.8%average 20-day move after past Distribution readings
+4.5%average move over the next 20 trading days in the last 5 years
±3.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Labcorp seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Labcorp averaged +4.5% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.2% | 4 of 5 |
| Next 10 trading days | +2.2% | 5 of 5 |
| Next 15 trading days | +4.1% | 5 of 5 |
| Next 20 trading days | +4.5% | 5 of 5 |
| Next 30 trading days | +3.3% | 5 of 5 |
For scale, LH’s typical 20-trading-day move in either direction is about 4.4%.
Labcorp market cap and key statistics
Labcorp’s market cap is $29.83B, with a P/E ratio of 29.2 and revenue of $14.59B over the last twelve months.
Valuation
- Market cap
- $29.83B
- P/E ratio
- 29.2
- Forward P/E
- 19.2
- EPS, TTM
- $12.20
- Gekko Fair Value
- $346.56
Trading
- Volume
- 773,385
- Avg volume, 20 days
- 750,407
- 52-week high
- $371.00
- 52-week low
- $244.52
- Shares outstanding
- 81.20M
Financials
- Revenue, TTM
- $14.59B
- Profit margin
- 6.9%
- Return on equity
- 11.4%
- Quarterly earnings growth, YoY
- +3.2%
Risk and income
- Beta
- 0.83
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±4.4%
- Dividend yield
- 0.80%
Labcorp stock news this week
Coverage of Labcorp this week reads positive: 15 positive, 6 neutral and 1 negative headlines.
- Form 8K Labcorp Holdings Inc For: 4 November By Investing.comInvesting.com Canada, Nov 4
- Labcorp to Speak at the UBS Global Healthcare ConferencePR Newswire, Nov 4
- Labcorp Director Richelle P. Parham Sells 1,078 Shares at $361.22 EachKalkine Media, Nov 3
- Insider Selling: Labcorp (NYSE:LH) Director Sells 1,078 Shares of StockMarketBeat, Nov 3
- Form 4 Labcorp Holdings Inc: Akinbolade Oyegunwa (EVP, CIO & CTO) For: 1 November By Investing.comInvesting.com India, Nov 3
- Form 4 Labcorp Holdings Inc: Bryan T. Vaughn (EVP and President, Diagnostics) For: 1 November By Investing.comInvesting.com India, Nov 3
Labcorp peers
Labcorp’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| GHGuardant Health | Neutral | 7.8% below |
| SOLVSolventum | Neutral | 18.5% below |
| EHCEncompass Health | Distribution | 17.9% above |
| BTSGBrightSpring Health Services | Distribution | 11.1% above |
| DVADaVita | Neutral | 13.3% below |
| ENSGEnsign | Neutral | 15.9% above |
A peer links to its own page where one exists.
Labcorp stock FAQ
What is Labcorp’s market cap?
Labcorp’s market cap is $29.83B at the Nov 4, 2026 close of $367.79, with 81.20M shares outstanding. The shares trade on a P/E ratio of 29.2.
What is the Labcorp stock forecast?
The consensus analyst 12-month price target for Labcorp is $382.25, +3.9% from the last close. Of the 13 firms that rated the stock in the last 90 days, 10 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Labcorp stock overvalued or undervalued?
On Gekko’s estimate Labcorp is overvalued: the Nov 4, 2026 close of $367.79 is 6.1% above Gekko Fair Value of $346.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Labcorp report earnings next?
Labcorp is expected to report on Feb 16, 2027, before the market opens (103 days away). Analysts expect earnings of $4.50 per share on revenue of $3.75B. Labcorp beat the earnings estimate in 8 of its last 8 reports, moving 3.6% on average across the report.
What is Labcorp’s 52-week high and low?
Labcorp’s 52-week high is $371.00 and its 52-week low is $244.52; it closed at $367.79 on Nov 4, 2026, +42.6% over the past year.
Is Labcorp stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Labcorp the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.